12
Participants
Start Date
May 30, 2017
Primary Completion Date
September 21, 2018
Study Completion Date
September 21, 2018
Empagliflozin
Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response
Anakinra
IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level
oral placebo (winthrop tablet)
subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
subcutaneous placebo (0.67 ml of 0.9% sodium chloride)
subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'
University Hospital Basel, Department of Endocrinology, Diabetes and Metabolism, Basel
University Hospital, Basel, Switzerland
OTHER